The Interplay Between DNA Topoisomerase 2α Post-translational Modifications and Drug Resistance

Overview

Journal Cancer Drug Resist

Date 2022 May 18

PMID 35582608

Authors

Christophe Lotz

Valerie Lamour

Affiliations

Soon will be listed here.

Abstract

The type 2 DNA topoisomerases (Top2) are conserved enzymes and biomarkers for cell proliferation. The catalytic activities of the human isoform Top2α are essential for the regulation of DNA topology during DNA replication, transcription, and chromosome segregation. Top2α is a prominent target for anti-cancer drugs and is highly regulated by post-translational modifications (PTM). Despite an increasing number of proteomic studies, the extent of PTM in cancer cells and its importance in drug response remains largely uncharacterized. In this review, we highlight the different modifications affecting the human Top2α in healthy and cancer cells, taking advantage of the structure-function information accumulated in the past decades. We also overview the regulation of Top2α by PTM, the level of PTM in cancer cells, and the resistance to therapeutic compounds targeting the Top2 enzyme. Altogether, this review underlines the importance of future studies addressing more systematically the interplay between PTM and Top2 drug resistance.

Citing Articles

Targeting TOP2A in Ovarian Cancer: Biological and Clinical Implications.

Borella F, Fucina S, Seminara Y, Denti P, Ferraioli D, Bertero L Curr Oncol. 2024; 31(12):8054-8074.

PMID: 39727717 PMC: 11674396. DOI: 10.3390/curroncol31120594.

Bioinformatic Analysis of Topoisomerase IIα Reveals Interdomain Interdependencies and Critical C-Terminal Domain Residues.

Endsley C, Moore K, Townsley T, Durston K, Deweese J Int J Mol Sci. 2024; 25(11).

PMID: 38891861 PMC: 11172036. DOI: 10.3390/ijms25115674.

Emerging role of MYB transcription factors in cancer drug resistance.

Biersack B, Hopfner M Cancer Drug Resist. 2024; 7:15.

PMID: 38835346 PMC: 11149108. DOI: 10.20517/cdr.2023.158.

Modeling allosteric mechanisms of eukaryotic type II topoisomerases.

Evoli S, Kariyawasam N, Nitiss K, Nitiss J, Wereszczynski J Biophys J. 2024; 123(12):1620-1634.

PMID: 38720465 PMC: 11213992. DOI: 10.1016/j.bpj.2024.05.004.

Enzymatic Processing of DNA-Protein Crosslinks.

Essawy M, Campbell C Genes (Basel). 2024; 15(1).

PMID: 38254974 PMC: 10815813. DOI: 10.3390/genes15010085.

References

Saijo M, Enomoto T, Hanaoka F, Ui M . Purification and characterization of type II DNA topoisomerase from mouse FM3A cells: phosphorylation of topoisomerase II and modification of its activity. Biochemistry. 1990; 29(2):583-90. DOI: 10.1021/bi00454a036. View

Ali Y, Abd Hamid S . Human topoisomerase II alpha as a prognostic biomarker in cancer chemotherapy. Tumour Biol. 2015; 37(1):47-55. DOI: 10.1007/s13277-015-4270-9. View

Wagner S, Beli P, Weinert B, Nielsen M, Cox J, Mann M . A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles. Mol Cell Proteomics. 2011; 10(10):M111.013284. PMC: 3205876. DOI: 10.1074/mcp.M111.013284. View

Vassetzky Y, Alghisi G, Gasser S . DNA topoisomerase II mutations and resistance to anti-tumor drugs. Bioessays. 1995; 17(9):767-74. DOI: 10.1002/bies.950170906. View

Blower T, Bandak A, Lee A, Austin C, Nitiss J, Berger J . A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents. Nucleic Acids Res. 2019; 47(15):8163-8179. PMC: 6735899. DOI: 10.1093/nar/gkz579. View

Kang X, Song C, Du X, Zhang C, Liu Y, Liang L . PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep. 2015; 5:17873. PMC: 4674714. DOI: 10.1038/srep17873. View

Wendorff T, Schmidt B, Heslop P, Austin C, Berger J . The structure of DNA-bound human topoisomerase II alpha: conformational mechanisms for coordinating inter-subunit interactions with DNA cleavage. J Mol Biol. 2012; 424(3-4):109-24. PMC: 3584591. DOI: 10.1016/j.jmb.2012.07.014. View

Dawlaty M, Malureanu L, Jeganathan K, Kao E, Sustmann C, Tahk S . Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell. 2008; 133(1):103-15. PMC: 2693193. DOI: 10.1016/j.cell.2008.01.045. View

Alchanati I, Teicher C, Cohen G, Shemesh V, Barr H, Nakache P . The E3 ubiquitin-ligase Bmi1/Ring1A controls the proteasomal degradation of Top2alpha cleavage complex - a potentially new drug target. PLoS One. 2009; 4(12):e8104. PMC: 2779455. DOI: 10.1371/journal.pone.0008104. View

10.

Choudhary C, Weinert B, Nishida Y, Verdin E, Mann M . The growing landscape of lysine acetylation links metabolism and cell signalling. Nat Rev Mol Cell Biol. 2014; 15(8):536-50. DOI: 10.1038/nrm3841. View

11.

Shapiro P, Whalen A, Tolwinski N, Wilsbacher J, Froelich-Ammon S, Garcia M . Extracellular signal-regulated kinase activates topoisomerase IIalpha through a mechanism independent of phosphorylation. Mol Cell Biol. 1999; 19(5):3551-60. PMC: 84147. DOI: 10.1128/MCB.19.5.3551. View

12.

Udeshi N, Svinkina T, Mertins P, Kuhn E, Mani D, Qiao J . Refined preparation and use of anti-diglycine remnant (K-ε-GG) antibody enables routine quantification of 10,000s of ubiquitination sites in single proteomics experiments. Mol Cell Proteomics. 2012; 12(3):825-31. PMC: 3591673. DOI: 10.1074/mcp.O112.027094. View

13.

Povlsen L, Beli P, Wagner S, Poulsen S, Sylvestersen K, Poulsen J . Systems-wide analysis of ubiquitylation dynamics reveals a key role for PAF15 ubiquitylation in DNA-damage bypass. Nat Cell Biol. 2012; 14(10):1089-98. DOI: 10.1038/ncb2579. View

14.

Takano H, Kohno K, Ono M, Uchida Y, Kuwano M . Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 1991; 51(15):3951-7. View

15.

Corbett A, DeVore R, Osheroff N . Effect of casein kinase II-mediated phosphorylation on the catalytic cycle of topoisomerase II. Regulation of enzyme activity by enhancement of ATP hydrolysis. J Biol Chem. 1992; 267(28):20513-8. View

16.

Agostinho M, Santos V, Ferreira F, Costa R, Cardoso J, Pinheiro I . Conjugation of human topoisomerase 2 alpha with small ubiquitin-like modifiers 2/3 in response to topoisomerase inhibitors: cell cycle stage and chromosome domain specificity. Cancer Res. 2008; 68(7):2409-18. DOI: 10.1158/0008-5472.CAN-07-2092. View

17.

Lane A, Gimenez-Abian J, Clarke D . A novel chromatin tether domain controls topoisomerase IIα dynamics and mitotic chromosome formation. J Cell Biol. 2013; 203(3):471-86. PMC: 3824022. DOI: 10.1083/jcb.201303045. View

18.

Eguren M, Alvarez-Fernandez M, Garcia F, Lopez-Contreras A, Fujimitsu K, Yaguchi H . A synthetic lethal interaction between APC/C and topoisomerase poisons uncovered by proteomic screens. Cell Rep. 2014; 6(4):670-83. DOI: 10.1016/j.celrep.2014.01.017. View

19.

Senturk J, Bohlman S, Manfredi J . Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53. Oncogene. 2017; 36(44):6085-6096. PMC: 5987529. DOI: 10.1038/onc.2017.229. View

20.

Wells N, Fry A, Guano F, Norbury C, Hickson I . Cell cycle phase-specific phosphorylation of human topoisomerase II alpha. Evidence of a role for protein kinase C. J Biol Chem. 1995; 270(47):28357-63. DOI: 10.1074/jbc.270.47.28357. View